One year in review 2018: systemic lupus erythematosus.
One year in review 2018: systemic lupus erythematosus.
复制标题
DOI：
--
复制
发表时间：
2018-09
影响因子：
3.7
通讯作者：
M. Di Battista;E. Marcucci;E. Elefante;A. Tripoli;G. Governato;D. Zucchi;C. Tani;A. Alunno
中科院分区：
文献类型：
--
作者：
M. Di Battista;E. Marcucci;E. Elefante;A. Tripoli;G. Governato;D. Zucchi;C. Tani;A. Alunno
系统性红斑狼疮（SLE）是一种全身性自身免疫性疾病，其特征在于广泛的临床表现，部分与疾病本身有关，但也与其合并症和药物不良反应有关。继以往的年度审查，我们专注于SLE的临床特征，致病途径，特定器官受累的生物标志物和治疗策略的新见解。我们最后集中在SLE方面，可能会显着影响患者的生活质量，需要通过开发和验证疾病特异性患者报告的结果进行详细调查。
Systemic lupus erythematosus (SLE) is a systemic autoimmune condition characterised by a wide spectrum of clinical manifestations, partly related to the disease itself, but also linked to its comorbidities and drugs adverse reactions. Following the previous annual reviews, we focused on new insights in SLE clinical features, pathogenic pathways, biomarkers of specific organ involvement and therapeutic strategies. We finally concentrated on SLE aspects that could significantly influence patients' quality of life and that need to be investigated in detail through the development and validation of disease-specific patient-reported outcomes.